- * Moderate or severe Hemophilia A (factor level ≤5%)
- * Receiving Helixate FS as on-demand treatment or prophylaxis therapy at time of informed consent
- * Patient age 14 to 29 years at the time of recruitment
- * Complete informed consent process and documentation; (Patients under age 18 must assent in addition to consent of legal guardian)
- * Willing/able to follow study protocol, including keeping a bleeding and treatment diary
- * Able to communicate clearly in either English or French - both written and verbal communication is essential.
Hemophilia A
Health Related Quality of Life of Youth and Young Adults With Hemophilia A
NCT01034904 | PHASE 3 | OBSERVATIONAL
The relevance of the study will be in establishing whether Health Related Quality of Life (HRQoL) measures obtained repeatedly during hemophilia care are sensitive to significant changes in health or personal circumstances related to the transition from youth to adulthood. This may support the future use of HRQoL measures as part of routine care in order to identify important changes that are not detectible by other clinical means.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Sick Kids Hospital
Toronto,Ontario,Canada,M5G1X8
CHU SainteJustine
Montreal,Quebec,Canada,H3T1C5
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov